Brookline Capital Management began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report released on Wednesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $42.00 target price on the stock.
Shares of NASDAQ MNPR opened at $9.95 on Wednesday. The firm has a fifty day moving average of $16.17. Monopar Therapeutics has a fifty-two week low of $8.35 and a fifty-two week high of $48.00.
A hedge fund recently bought a new stake in Monopar Therapeutics stock. Bank of Montreal Can acquired a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 13,000 shares of the company’s stock, valued at approximately $216,000. Bank of Montreal Can owned approximately 0.12% of Monopar Therapeutics at the end of the most recent reporting period. 0.12% of the stock is currently owned by institutional investors and hedge funds.
Monopar Therapeutics Inc, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that has completed Phase II for the treatment of chemoradiation-induced severe oral mucositis; Camsirubicin, a proprietary doxorubicin analog that is in Phase II clinical trial for the treatment of adult and pediatric solid, and blood cancers; and MNPR-101, a humanized monoclonal antibody for treating cancer.
Recommended Story: What member countries make up the G-20?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.